Life sciences company Neogen (NASDAQ:NEOG) reported Q2 CY2026 results topping the market’s revenue expectations, but sales were flat year on year at $225.3 million. The company’s full-year revenue guidance of $882.5 million at the midpoint came in 3.9% above analysts’ estimates. Its non-GAAP profit of $0.09 per share was 58.8% above analysts’ consensus estimates.
Is now the time to buy Neogen? Find out by accessing our full research report, it’s free.
Neogen (NEOG) Q2 CY2026 Highlights:
- Revenue: $225.3 million vs analyst estimates of $212.5 million (flat year on year, 6% beat)
- Adjusted EPS: $0.09 vs analyst estimates of $0.06 (58.8% beat)
- Adjusted EBITDA: $45.4 million vs analyst estimates of $42.23 million (20.2% margin, 7.5% beat)
- EBITDA guidance for the upcoming financial year 2027 is $181 million at the midpoint, above analyst estimates of $178.6 million
- Operating Margin: 1.4%, up from -271% in the same quarter last year
- Free Cash Flow was -$5.67 million, down from $349,000 in the same quarter last year
- Market Capitalization: $2.05 billion
Company Overview
Founded in 1981 and operating at the intersection of food safety and animal health, Neogen (NASDAQ:NEOG) develops and manufactures diagnostic tests and related products to detect dangerous substances in food and pharmaceuticals for animal health.
Revenue Growth
Examining a company’s long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Thankfully, Neogen’s 13.2% annualized revenue growth over the last five years was solid. Its growth beat the average healthcare company and shows its offerings resonate with customers.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Neogen’s recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 3% over the last two years. 
This quarter, Neogen’s $225.3 million of revenue was flat year on year but beat Wall Street’s estimates by 6%.
Looking ahead, sell-side analysts expect revenue to decline by 3.2% over the next 12 months, similar to its two-year rate. This projection doesn’t excite us and implies its newer products and services will not accelerate its top-line performance yet.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Adjusted Operating Margin
Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.
Although Neogen was profitable this quarter from an operational perspective, it’s generally struggled over a longer time period. Its expensive cost structure has contributed to an average adjusted operating margin of negative 22.1% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It’s hard to trust that the business can endure a full cycle.
Analyzing the trend in its profitability, Neogen’s adjusted operating margin decreased by 9.5 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 4.7 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.
In Q2, Neogen generated an adjusted operating margin profit margin of 17.4%, up 288.4 percentage points year on year. This increase was a welcome development and shows it was more efficient.
Earnings Per Share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.
Sadly for Neogen, its EPS declined by 11.4% annually over the last five years while its revenue grew by 13.2%. However, its adjusted operating margin actually improved during this time, telling us that non-fundamental factors such as interest expenses and taxes affected its ultimate earnings.
We can take a deeper look into Neogen’s earnings to better understand the drivers of its performance. As we mentioned earlier, Neogen’s adjusted operating margin expanded this quarter but declined by 9.5 percentage points over the last five years. Its share count also grew by 101%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders. 
In Q2, Neogen reported adjusted EPS of $0.09, up from $0.05 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Neogen’s full-year EPS to shrink by 7.3% from $0.32 to $0.30.
Key Takeaways from Neogen’s Q2 Results
It was good to see Neogen beat analysts’ EPS expectations this quarter. We were also excited its revenue outperformed Wall Street’s estimates by a wide margin. Zooming out, we think this was a good print with some key areas of upside. The stock traded up 7.1% to $10.07 immediately following the results.
Indeed, Neogen had a rock-solid quarterly earnings result, but is this stock a good investment here? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).